FTSE News: FTSE 100, FTSE 250, and FTSE 400 investment news
FTSE market news from the London Stock Exchange: FTSE 100, FTSE 250, and FTSE 400

Latest FTSE News:

  • Miners gain, house builders see declines

  • Oil, miners higher in London

  • Telecoms, retailers see gains

  • Pharma lower in London

  • British Energy drops on nuclear plant delays

  • Home builders see gains in London

  • House builders, property developers down in London

  • Brewers higher on bids rumors

  • Oil sector, banks mixed in London

  • BP, Royal Dutch Shell gain on higher oil prices

  • FTSE news feed

    Recommended equities news sites

  • Eurofirst News
  • Tokyo Market News
  • NYSE News
  • Insurance: Car & Home
  • FTSE
  • London Stock Exchange
  •  

    July 4, 2006

    Weak pharma hurts FTSE 100

    Filed under: Companies, British Land, Land Securities, Marks & Spencer, Vodafone, AstraZeneca, Hammerson, Shaftesbury, St Modwen, Great Portland Estates

    Equities markets in London were mixed but closed very close to Monday’s levels on Tuesday as investors indulged in profit-taking after gains in the past four trading sessions. The FTSE 100 dropped 0.02 percent, less than a point, to 4,883.5. The FTSE 250 was up 0.09 percent to 9,505.6. With US markets closed for the Independence Day holiday, volume was light with only 1.9 billion shares trading hands.

    The property sector saw gains among both blue-chip and mid-cap stocks. On the 100, both British Land and Land Securities added 2.8 percent, to £13.33 and £18.79 respectively. Hammerson gained 3.1 percent to £12.41. Over on the 250, Shaftesbury was up 4.8 percent to 549p, while St Modwen rose 4.9 percent to 469p and Great Portland Estates gained 534¾p.

    Among telecoms, Vodafone was up 1 percent to 119p on positive comments from Deutsche Bank.

    Positive sentiment from Goldman Sachs sent Marks & Spencer 1.9 percent higher to 598p, as it added the retailer to its ‘Conviction Buy List’.

    On the other hand AstraZeneca dropped 2.7 percent to £32.19 when ING downgraded the drug maker from “buy” to “hold”, saying that its 12.7 percent share price rise in the past month raises issues of valuation.





    Latest Equities News:

  • Europe, US, most Asia markets lower on news, data

  • Equities decline globally on European debt concerns

  • Most global equities markets see declines on commodities prices

  • Europe, Asia markets mixed as Wall Street declines

  • European, US markets see gains as Asia markets remain mixed

  • European equities decline on lower credit rating for Greece

  • European equities markets gain, helped by US jobs report

  • Most global equities markets in decline

  • Europe, US, Asia markets all see declines

  • London markets see gains as most European markets retreat

  • FTSE News copyright 2012 Central Consultants